How does defibrotide sodium prevent or treat liver blood clots after stem cell transplant?
Defibrotide sodium enhances the body's natural clot-dissolving enzyme (plasmin) to break down fibrin clots in liver blood vessels, while also protecting the delicate endothelial cells that line those vessels. Clinical trials show a 25–30% reduction in veno-occlusive disease risk when given prophylactically [4].
The FDA approved defibrotide sodium in 2016 based on a treatment-IND study showing that 39% of patients with active hepatic veno-occlusive disease (VOD/SOS) achieved complete resolution of symptoms within 100 days of starting the drug [6]. This is remarkable because VOD/SOS is a life-threatening complication with historically poor outcomes—many patients develop liver failure and multi-organ shutdown. Defibrotide sodium is one of the few medicines proven to reverse this trajectory.
Inside your liver, defibrotide sodium works like a microscopic plumber. It boosts your body's natural plasmin enzyme, which dissolves fibrin (the protein glue holding blood clots together). At the same time, it calms down the inflamed endothelial cells lining your liver's tiny blood vessels, reducing the swelling and leakiness that trigger clot formation in the first place [1]. Think of it as both unclogging the drain and reducing the inflammation that caused the blockage.
In real-world transplant practice, defibrotide sodium is given as a 21-day IV infusion starting either before transplant (prophylaxis) or within 7 days of VOD/SOS diagnosis (treatment). The dose is 6.25 mg per kilogram of body weight, four times daily—so a 70 kg adult receives about 1,750 mg total per day. Most transplant centers pre-authorize insurance coverage because the drug is considered standard-of-care for high-risk patients [9].
Ask your transplant team: 'Am I at high risk for VOD/SOS based on my conditioning regimen and donor type?' If yes, request defibrotide prophylaxis and confirm your insurance pre-authorization at least 2 weeks before transplant day.